Autoantibodies as predictors for clinical outcome and toxicity for immunotherapy
Peripheral blood autoantibody signatures might be useful biomarkers of immunotherapy outcome. Signatures predicting melanoma recurrence and toxicity during adjuvant immunotherapy were recently presented. Whether autoantibodies are bystanders or have a pathophysiologic role is unknown, and further ef...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 15, 2022
|
| In: |
Clinical cancer research
Year: 2022, Volume: 28, Issue: 18, Pages: 3914-3916 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-22-1664 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-22-1664 Verlag, lizenzpflichtig, Volltext: https://aacrjournals.org/clincancerres/article/28/18/3914/708989/Autoantibodies-as-Predictors-for-Clinical-Outcome 
|
| Author Notes: | Jessica C. Hassel and Jason J. Luke |
| Summary: | Peripheral blood autoantibody signatures might be useful biomarkers of immunotherapy outcome. Signatures predicting melanoma recurrence and toxicity during adjuvant immunotherapy were recently presented. Whether autoantibodies are bystanders or have a pathophysiologic role is unknown, and further efforts are needed to investigate potential mechanisms and determine causation.See related article by Johannet et al., p. 4121 |
|---|---|
| Item Description: | Gesehen am 25.10.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-22-1664 |